Exercise-CTSS-AD Axis framework explains exercise's neuroprotective effects in Alzheimer's disease
Background
Current disease-modifying therapies for Alzheimer's disease (AD) targeting amyloid-β and tau have largely failed, underscoring an urgent need for innovative strategies. Cathepsin S (CTSS), a lysosomal cysteine protease, is upregulated in AD and acts as a 'multifaceted disruptor' linking neuroinflammation, blood-brain barrier (BBB) dysfunction, and Aβ metabolic dysregulation. While exercise is a validated non-pharmacological intervention for AD, its precise multi-target molecular mechanisms have remained elusive, leaving a critical gap in understanding its therapeutic potential.
Study Design
Researchers synthesized existing evidence to propose and substantiate the Exercise-CTSS-AD Axis hypothesis, detailing how exercise mitigates Alzheimer's disease pathology. They outlined specific molecular pathways by which exercise suppresses Cathepsin S (CTSS), a lysosomal cysteine protease, and its downstream effects on neuroinflammation, BBB integrity, and Aβ metabolism. This involved integrating data on exercise-induced myokines, senescent cell clearance, and AMPK-TFEB axis activation to construct a unifying molecular framework for exercise's pleiotropic benefits.
Results
The proposed Exercise-CTSS-AD Axis posits that exercise confers neuroprotection by suppressing CTSS through synergistic anti-inflammatory, anti-aging, and metabolic regulatory pathways. Exercise-induced myokines and clearance of senescent cells are hypothesized to inhibit CTSS transcription. Furthermore, activation of the AMPK-TFEB axis is proposed to enhance lysosomal function, thereby repressing CTSS enzymatic activity. This systemic CTSS suppression is theorized to preserve blood-brain barrier (BBB) integrity, ameliorate microglia-driven neuroinflammation, and restore Aβ homeostasis by reducing its production and enhancing clearance. The framework provides a unifying molecular explanation for the pleiotropic benefits of exercise.
It positions CTSS as a quantifiable biomarker for personalized exercise regimens and supports an innovative combinatorial strategy: Exercise + low-dose CTSS inhibitors as a disease-modifying therapy for AD.
Key Findings
- Exercise suppresses
CTSSvia synergistic anti-inflammatory, anti-aging, and metabolic regulatory pathways. - Exercise-induced myokines and senescent cell clearance inhibit
CTSStranscription. AMPK-TFEBaxis activation enhances lysosomal function to repressCTSSenzymatic activity.- Systemic
CTSSsuppression preserves BBB integrity, ameliorates neuroinflammation, and restores Aβ homeostasis. - The framework positions
CTSSas a quantifiable biomarker for personalized exercise regimens in AD.
Why It Matters
This framework offers a crucial molecular explanation for how exercise benefits Alzheimer's disease, moving beyond general 'healthy lifestyle' advice to specific mechanistic insights. For biohackers and clinicians, it highlights CTSS as a potential biomarker for tailoring exercise protocols, suggesting that monitoring CTSS levels could personalize exercise regimens for optimal neuroprotection. The practical takeaway is that exercise's therapeutic effects in AD are not random but operate through a specific, quantifiable pathway involving CTSS suppression. This also opens the door for novel combinatorial therapies, such as pairing exercise with low-dose CTSS inhibitors, potentially accelerating the development of more effective AD treatments.
alzheimers-disease
exercise
cathepsin-s
neuroprotection
neuroinflammation
blood-brain-barrier